Exagen's Q2 2025: Unpacking Contradictions in Volume Growth, ASP Expectations, and Biopharma Revenue
Generated by AI AgentAinvest Earnings Call Digest
Tuesday, Jul 29, 2025 3:17 pm ET1min read
XGN--
Aime Summary
Revenue and Volume Growth:
- Exagen Inc.XGN-- reported record revenue of $17.2 million for Q2 2025, representing 14% year-over-year growth.
- The growth was driven by substantial AVISE CTD test volume growth, which was the best since strategic adjustments in 2023, and improved revenue cycle efforts.
Average Revenue per Territory Increase:
- The average revenue per territory reached just over $430,000 for the quarter, a 50% increase since 2021 when John Aballi joined.
- This increase reflects improved commercial leverage and the effectiveness of sales expansion initiatives.
New Biomarkers and ASP Expansion:
- The trailing 12-month AVISE CTD ASP grew $27 year-over-year to $428, driven by new biomarkers launched in January.
- Despite a conservative approach to accrual rates, this expansion is expected to continue as patient deductibles max out and revenue cycles complete.
Pipeline and R&D Progress:
- Exagen's R&D pipeline is advancing, with lupus nephritis and kidney damage markers showing promising results, and the anti-PAD4 biomarkers planned for launch in 2026.
- The company is focused on securing reimbursement for new tools, which will allow for broader patient access.
Revenue and Volume Growth:
- Exagen Inc.XGN-- reported record revenue of $17.2 million for Q2 2025, representing 14% year-over-year growth.
- The growth was driven by substantial AVISE CTD test volume growth, which was the best since strategic adjustments in 2023, and improved revenue cycle efforts.
Average Revenue per Territory Increase:
- The average revenue per territory reached just over $430,000 for the quarter, a 50% increase since 2021 when John Aballi joined.
- This increase reflects improved commercial leverage and the effectiveness of sales expansion initiatives.
New Biomarkers and ASP Expansion:
- The trailing 12-month AVISE CTD ASP grew $27 year-over-year to $428, driven by new biomarkers launched in January.
- Despite a conservative approach to accrual rates, this expansion is expected to continue as patient deductibles max out and revenue cycles complete.
Pipeline and R&D Progress:
- Exagen's R&D pipeline is advancing, with lupus nephritis and kidney damage markers showing promising results, and the anti-PAD4 biomarkers planned for launch in 2026.
- The company is focused on securing reimbursement for new tools, which will allow for broader patient access.
Discover what executives don't want to reveal in conference calls
Latest Articles
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue

Comments
No comments yet